Heidelberg Pharma Announces Several Presentations of Research Results on ATAC Technology at the ASH Annual Meeting 2020
- Heidelberg Pharma presents the design for the planned clinical study with HDP-101
- Partner MD Anderson Cancer Center presents in an oral presentation preclinical data with HDP-101 on the induction of an immune response against multiple myeloma by HDP-101
- Licensing partner Magenta presents further preclinical data on the ATAC candidate MGTA-117
Heidelberg Pharma AG today announced that it will present the design for the planned clinical trial with HDP-101 at the 62nd Annual Meeting of the American Society of Hematology (ASH). In addition, partners MD Anderson Cancer Center, Houston, TX, USA, (MD Anderson) and Magenta Therapeutics, Cambridge, MA, USA, (Magenta) (NASDAQ: MGTA) will present data on the ATAC technology. The conference will take place from 5th to 8th December 2020 in a virtual format.